Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on promising checkpoint inhibitor combination approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.